entospletinib + cytarabine + daunorubicin

**Entospletinib + cytarabine + daunorubicin** is a triple drug regimen used experimentally for the treatment of acute myeloid leukemia (AML), notably in molecularly defined subtypes such as NPM1-mutated or MLL-rearranged AML[2][5]. **Entospletinib** is a selective small molecule inhibitor of spleen tyrosine kinase (SYK), designed to block B-cell receptor signaling and induce apoptosis in hematologic malignancies[1][5]. **Cytarabine** is a nucleoside analog, functioning as an antimetabolite that inhibits DNA synthesis, and **daunorubicin** is an anthracycline chemotherapy agent that intercalates with DNA and inhibits topoisomerase II, leading to cytotoxicity in rapidly dividing cells. This combination is typically administered as induction therapy for AML, with entospletinib investigated to enhance efficacy in specific genetically defined patient groups by targeting leukemic cell survival and proliferation pathways in synergy with standard chemotherapy[2][5].

Brand names

No unique brand name for the combinationcytarabine (Cytosar-U, others)daunorubicin (Cerubidine, others)entospletinib (no marketed brand name)

Other names

entospletinib + cytarabine + daunorubicinentospletinib-based induction chemotherapy